Labeled Nucleotide Composition for Quantitative RNA Labeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for labeling RNA in polynucleotide arrays are susceptible to reverse-transcriptase reaction bias, and existing labeling techniques are not quantitative due to variations in guanine content among different miRNAs, making them unsuitable for accurate diagnostic and analytical purposes.
Innovation Solution
Development of novel labeled nucleotide compositions with a structure comprising a phosphate group, a nucleoside moiety, a linking group, and an observable label moiety, which are used in conjunction with an enzyme having RNA ligation activity to label RNA samples, allowing for specific binding and detection on arrays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing labeling techniques are used, then RNA can be labeled, but the labeling is not quantitative due to variations in guanine content among different miRNAs
Solution Approach 1:
The patent changes the labeling mechanism from sequence-dependent (guanine content-based) to sequence-independent by using a polymerase-based method that incorporates labeled nucleotides throughout the entire RNA molecule. This parameter change in the labeling mechanism eliminates variability based on guanine content and enables quantitative measurements across different miRNA sequences.
Solution Approach 2:
The patent replaces the chemical labeling mechanism (which depends on guanine content and is non-quantitative) with an enzymatic polymerase-based labeling system. This substitution uses enzyme-catalyzed nucleotide incorporation to achieve uniform, quantitative labeling regardless of the RNA sequence composition.
2Measurement precision
If reverse-transcriptase reaction is used for labeling, then RNA can be labeled, but the method is susceptible to reverse-transcriptase reaction bias
Solution Approach 1:
The patent replaces the reverse-transcriptase enzyme system with a different polymerase-based labeling system. This substitution eliminates the harmful bias introduced by reverse-transcriptase while maintaining the ability to label RNA quantitatively and accurately.
Solution Approach 2:
The patent introduces a labeled nucleotide analog as an intermediary that is incorporated by a polymerase enzyme. This intermediary mechanism allows for quantitative labeling without relying on the biased reverse-transcriptase reaction, as the labeled nucleotides are incorporated throughout the entire RNA molecule in a uniform manner.
3Measurement precision
If streptavidin-linked Alexa dye is used for labeling, then RNA can be labeled, but the streptavidin-dye and streptavidin-biotin-RNA stochiometry is difficult to quantify
Solution Approach 1:
The patent extracts and eliminates the complex streptavidin-biotin-Alexa dye system from the labeling process. By using a direct polymerase-based incorporation method with labeled nucleotides, the patent removes the need for separate staining and binding steps, thereby simplifying the system and enabling accurate quantification of labeling stochiometry.
Solution Approach 2:
The patent replaces the indirect streptavidin-linked dye system with a direct enzymatic incorporation system. This substitution uses polymerase-catalyzed incorporation of labeled nucleotides directly into the RNA, eliminating the complex multi-component system and enabling straightforward quantification of labeling efficiency and stochiometry.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution enables efficient and quantitative labeling of RNA, providing accurate data on binding patterns and concentrations of miRNAs, thereby enhancing the diagnostic potential of RNA analysis in polynucleotide arrays.
Implementation Method 1
contacting the sample with an enzyme having an RNA ligation activity in the presence of the labeled nucleotide composition under conditions sufficient to result in coupling of the labeled nucleotide composition to the RNA in the sample
Implementation Method 2
The labeled nucleotide compositions have the structure P1-Nus-P2-Lnk-Obs wherein P1 is a phosphate group, Nus is a nucleoside moiety, P2 is a phosphate group, Lnk is a linking group, and Obs is an observable label moiety
Data Source
AI summary
Embodiments of labeled nucleotide compositions are described. Methods are described in which a sample containing RNA is contacted with an enzyme having an RNA ligation activity in the presence of a labeled nucleotide composition to provide labeled RNA. Methods of performing an array analysis of a labeled RNA sample are also described.